Rainbow Children's Medicare has released its Integrated Annual Report for FY2025-26, providing shareholders access via its official investor relations portal. The report covers the period from April 1, 2025 to March 31, 2026 and was approved by the Board of Directors on May 23, 2026. Company Secretary and Compliance Officer Shreya Mitra signed the related intimation on July 4, 2026, in compliance with Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholders without registered email addresses can access the report through the company's official web link.

Report Access Details

Shareholders can access the Integrated Annual Report for FY2025-26 through the following official channel:

Financial Performance

FY2026 marked a strong financial year for Rainbow Children's Medicare, with the company delivering its highest-ever revenue, EBITDA, and PAT on a consolidated basis. The following table summarises the key consolidated financial metrics:

*Subject to shareholder approval at the ensuing AGM.

Revenue grew 12.35% to ₹17,030.77 million, driven by a 6.22% rise in inpatient volumes, a 12.07% increase in outpatient volumes, and an 11.45% increase in Average Revenue per Occupied Bed (ARPOB). EBITDA grew 11.08% to ₹5,441.67 million, while consolidated net profit after tax rose 15.28% to ₹2,815.44 million. On a standalone basis, income rose 5.70% to ₹15,891.14 million and net profit after tax grew 5.23% to ₹2,500.16 million.

Operational Highlights

FY2026 was a landmark year for network expansion. Rainbow added 440 capacity beds — the highest annual addition in its history — taking total bed capacity to 2,375 (excluding the 60-bed HRBR hospital in Bengaluru, which commenced operations on May 1, 2026). Key operational metrics are presented below:

The company also completed two strategic acquisitions during the year: Prashanthi Medicare Private Limited (Warangal, Telangana; 100 beds; effective July 1, 2025) for approximately ₹33 crores, and Pratiksha Women & Child Care Hospital Private Limited (Guwahati, Northeast; 150 beds; effective August 18, 2025) for approximately ₹171 crores. These acquisitions contributed ₹191.52 million and ₹648.70 million to consolidated revenue, respectively.

Capital Allocation and Balance Sheet

As of March 31, 2026, cash, cash equivalents, fixed deposits, and mutual fund investments stood at ₹5,942 million. Capital expenditure during FY2026 amounted to ₹2,170 million, directed towards expanding and strengthening capabilities across existing and upcoming hospitals. The company's net block of assets grew by ₹791.51 million to ₹8,924.33 million, while capital work-in-progress stood at ₹757.51 million, linked to upcoming projects in Gurugram, Pune, and Hennur.

The Board has recommended a final dividend of ₹3.50 per equity share of face value ₹10 each (35% of face value) for FY2025-26, subject to shareholder approval at the 28th Annual General Meeting scheduled for July 29, 2026. The record date for dividend entitlement has been fixed as July 21, 2026.

Network Expansion and Strategic Outlook

Rainbow's network as of March 31, 2026, spans 24 hospitals and 5 clinics across 9 cities, with a strong hub-and-spoke model anchoring specialized pediatric and perinatal care. Key upcoming projects include a regional hub hospital in Coimbatore (approximately 130 beds, expected H2 FY2028), hub and spoke hospitals in Gurugram (approximately 325 beds and 125 beds respectively), and a regional hub hospital in Pune (approximately 150 beds). The company aims to add over 2,500 beds over the next five years, targeting a network of approximately 5,000 beds with an investment of around ₹2,200 crore.

As of March 31, 2026, the company employed 6,397 permanent and contract staff, with women constituting 62% of the total workforce. The Board also noted that the company's ESOP Scheme 2025 was implemented during the year, with 246,470 stock options granted across three tranches.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE961O01016/4e1945aa-555d-4287-ab65-8fa14c169615.pdf

Rainbow Childrens Medicare filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 with the National Stock Exchange of India and BSE Limited. The disclosure, submitted on July 4, 2026, includes an Independent Practitioners’ Reasonable Assurance Report on the BRSR Core Indicators provided by M/s. Adwin Advisory Private Limited. This filing forms part of the company's Integrated Annual Report for FY26.

The company reported that it operates on a consolidated basis, covering 23 hospitals and 5 clinics across six states in India. As of the end of the financial year, the total workforce stood at 6,397 employees, comprising 2,446 male and 3,951 female staff members. The report noted that 100% of permanent employees were covered by health and accident insurance. Additionally, the Board of Directors includes one female member out of seven, representing 14% of the board.

Environmental and Operational Metrics

The BRSR report details the company's environmental footprint, including energy consumption, water usage, and waste management. Rainbow Childrens Medicare reported initiatives such as Solar Rooftop installations at its Rajahmundry facility and the implementation of solar water heaters in new projects to reduce carbon emissions. The company stated that it is compliant with all relevant environmental regulations, including the Water (Prevention and Control of Pollution) Act and the Air (Prevention and Control of Pollution) Act, with no non-compliances recorded during the year.

Financial and Governance Details

The document outlines the company's corporate structure, listing eight subsidiaries, including Rainbow Children’s Hospital Private Limited and Rosewalk Healthcare Private Limited. The Corporate Social Responsibility (CSR) committee confirmed that CSR provisions are applicable, with a reported turnover of ₹15,456.60 million and a net worth of ₹16,890.57 million on a standalone basis. The highest authority responsible for implementing the Business Responsibility policy is Dr. Ramesh Kancharla, Chairman & Managing Director.

Assurance and Stakeholder Engagement

M/s. Adwin Advisory Private Limited provided reasonable assurance for the nine BRSR Core indicators, covering areas such as greenhouse gas emissions, water footprint, and employee well-being. The assurance engagement was conducted in accordance with International Standard on Assurance Engagements (ISAE) 3000 (Revised). The company emphasized its stakeholder engagement processes, identifying patients, healthcare professionals, employees, and investors as key groups, and noted that it had received 30 complaints regarding responsible business conduct principles, of which 27 were resolved as of March 31, 2026.